PYC Therapeutics Highlights Advancement of Ocular and CNS Development Programs And Continued U.S. Expansion in Second Quarter 2021 Update

SAN DIEGO and PERTH, Australia: SAN DIEGO and PERTH, Australia, July 28, 2021 /PRNewswire/ — PYC Therapeutics (ASX: PYC), a biotechnology company combining two complementary platform technologies (selective drug delivery and precision drug design) to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, today announced a second quarter update highlighting the progress of its development pipeline, growth of its U.S. operations and upcoming milestones.
Click here to view original post